Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View item
  • Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.

Thumbnail
View/Open
Accepted version (254.8Kb)
Date
2021-01-08
ICR Author
Kote-Jarai, Zsofia
Eeles, Rosalind
Author
Karunamuni, RA
Huynh-Le, M-P
Fan, CC
Thompson, W
Eeles, RA
Kote-Jarai, Z
Muir, K
Lophatananon, A
UKGPCS collaborators
Schleutker, J
Pashayan, N
Batra, J
APCB BioResource (Australian Prostate Cancer BioResource)
Grönberg, H
Walsh, EI
Turner, EL
Lane, A
Martin, RM
Neal, DE
Donovan, JL
Hamdy, FC
Nordestgaard, BG
Tangen, CM
MacInnis, RJ
Wolk, A
Albanes, D
Haiman, CA
Travis, RC
Stanford, JL
Mucci, LA
West, CML
Nielsen, SF
Kibel, AS
Wiklund, F
Cussenot, O
Berndt, SI
Koutros, S
Sørensen, KD
Cybulski, C
Grindedal, EM
Park, JY
Ingles, SA
Maier, C
Hamilton, RJ
Rosenstein, BS
Vega, A
IMPACT Study Steering Committee and Collaborators
Kogevinas, M
Penney, KL
Teixeira, MR
Brenner, H
John, EM
Kaneva, R
Logothetis, CJ
Neuhausen, SL
Razack, A
Newcomb, LF
Canary PASS Investigators
Gamulin, M
Usmani, N
Claessens, F
Gago-Dominguez, M
Townsend, PA
Roobol, MJ
Zheng, W
Profile Study Steering Committee
Mills, IG
Andreassen, OA
Dale, AM
Seibert, TM
PRACTICAL Consortium
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
<h4>Background</h4>Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).<h4>Materials and method</h4>180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.<h4>Results</h4>166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.<h4>Conclusions</h4>Incorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.
URI
https://repository.icr.ac.uk/handle/internal/4968
DOI
https://doi.org/10.1038/s41391-020-00311-2
https://doi.org/10.1038/s41391-020-00311-2
 
Collections
  • Genetics and Epidemiology
  • Radiotherapy and Imaging
Subject
UKGPCS collaborators
APCB BioResource (Australian Prostate Cancer BioResource)
IMPACT Study Steering Committee and Collaborators
Canary PASS Investigators
Profile Study Steering Committee
PRACTICAL Consortium
Research team
Oncogenetics
Language
eng
Date accepted
2020-12-04
License start date
2021-01-08
Citation
Prostate cancer and prostatic diseases, 2021

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.